Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte Inc (NASDAQ: HUMA) is a clinical-stage biotechnology pioneer developing universally implantable bioengineered human tissues for vascular repair and regenerative medicine. This dedicated news hub provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access timely press releases and analysis covering HUMA's progress in vascular trauma solutions, hemodialysis access innovations, and peripheral artery disease treatments. Our curated collection includes updates on FDA designations, trial results, manufacturing partnerships, and scientific publications - all critical for evaluating the company's position in advanced tissue engineering.
Key focus areas include acellular tissue platform developments, late-stage clinical trial outcomes, and commercialization strategies for shelf-ready vascular conduits. Bookmark this page to efficiently track Humacyte's progress in transforming surgical practices through its disruptive approach to regenerative medicine.
Humacyte (Nasdaq: HUMA) has received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency for its Symvess product. This approval enables healthcare professionals at Department of Defense (DOD) and Veterans Affairs facilities to access Symvess for treating military service members, veterans, and other patients.
Symvess, an acellular tissue engineered vessel, received FDA approval in December 2024 for extremity vascular trauma indication. The ECAT system integration represents a significant milestone in making the product accessible to military healthcare providers. However, for uses beyond the FDA-approved indication, Symvess remains investigational and requires further regulatory approval.
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.
The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.
Humacyte (NASDAQ: HUMA), a clinical-stage biotechnology company focused on developing universally implantable, bioengineered human tissue, has scheduled its Q1 2025 financial results release and corporate update for May 13, 2025. The company will host a conference call and webcast at 8:30 AM ET.
U.S. investors can join via 1-877-704-4453, while international participants can dial 1-201-389-0920 using conference ID 13753487. The webcast will be available 15 minutes before the call and remain accessible on the company's investor relations website for at least 30 days afterward.
Humacyte (NASDAQ: HUMA) announced its Q4 and full-year 2024 financial results, highlighting the FDA approval of Symvess™ for extremity vascular trauma treatment in December 2024. The company has initiated commercial launch with first sales in February 2025, with 34 hospitals starting the Value Analysis Committee approval process and three hospitals already approving purchases.
Financial highlights show no revenue for Q4 and full-year 2024. R&D expenses were $20.7M in Q4 2024 and $88.6M for the full year. Net loss increased to $148.7M for 2024, compared to $110.8M in 2023. The company reported $95.3M in cash and equivalents as of December 31, 2024, with an additional $46.6M raised through a public offering in March 2025.
Key developments include positive Phase 3 trial results for arteriovenous access in dialysis patients, plans for a supplemental BLA submission in H2 2026, and an upcoming IND filing in 2025 for coronary artery bypass grafting studies.
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale, has scheduled its Q4 and full-year 2024 financial results release for March 28, 2025.
The company will host a webcast and conference call at 8:30 a.m. ET on the same day. The webcast will be available 15 minutes before the call begins, and a replay will be accessible on the company's investor relations website for at least 30 days following the broadcast.
Humacyte (Nasdaq: HUMA) has announced the pricing of a public offering of 25,000,000 shares of common stock at $2.00 per share, expecting to raise gross proceeds of $50 million. The offering is set to close around March 27, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 3,750,000 shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers.
The net proceeds will be used to fund the commercialization of SYMVESS™ in vascular trauma indication, development of product candidates in Humacyte's pipeline, and for working capital and general corporate purposes.
Humacyte (Nasdaq: HUMA) has announced an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase up to an additional 15% of offered shares. TD Cowen, Barclays, and BTIG are serving as joint book-running managers, while H.C. Wainwright & Co. and The Benchmark Company act as lead managers.
The commercial-stage biotechnology platform company, focused on developing universally implantable bioengineered human tissues, intends to use the proceeds to fund:
- Commercialization of SYMVESS™ in vascular trauma indication
- Development of product candidates in pipeline
- Working capital and general corporate purposes
The offering will be made through a shelf registration statement previously filed and declared effective by the SEC. The final size, terms, and completion of the offering remain subject to market conditions.